- Home
- GUTS
GUTS
FRACTYL HEALTH INC
as 07-04-2025 11:35am EST
Stocks
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | BURLINGTON |
| Market Cap: | 58.8M | IPO Year: | 2024 |
| Target Price: | $10.00 | AVG Volume (30 days): | 938.9K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.87 - $4.92 | Next Earning Date: | 08-13-2025 |
| Revenue: | $60,000 | Revenue Growth: | -59.46% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest FRACTYL HEALTH INC News
GUTS Breaking Stock News: Dive into GUTS Ticker-Specific Updates for Smart Investing
MT Newswires
12 days ago
Fractyl Health Says Revita Sustains Weight Loss After GLP-1 Discontinuation
GlobeNewswire
13 days ago
Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy
GlobeNewswire
13 days ago
Fractyl Health Presents New Data at the American Diabetes Association’s 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models
MT Newswires
17 days ago
Fractyl Health Obtains 2 US Patents for Duodenal Resurfacing
GlobeNewswire
18 days ago
Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing
TipRanks
22 days ago
Biotech Alert: Searches spiking for these stocks today
GlobeNewswire
23 days ago
Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions
GlobeNewswire
a month ago
Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide
Compare GUTS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GUTS FRACTYL HEALTH INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.